Figure 10. The mitochondrial chaperone, HSPD1, predicts poor clinical outcome and tumor progression in lung cancer patients: Non-Smokers.

Note that the levels HSPD1 effectively predict overall survival A., as well as time to first progression and post-progression survival B., in the “non-smoking” patient population.